This study focuses on patients with Chronic Obstructive Pulmonary Disease (COPD), a long-term lung condition that causes breathing difficulties and frequent chest infections. The research examines how azithromycin, an antibiotic medication, can be used to manage severe mucus production in COPD patients.
The study aims to compare two different approaches for prescribing azithromycin in COPD patients over a 12-month period. In one group, the medication will be prescribed based on standardized management when patients experience severe mucus symptoms. In the other group, the prescription will be based on analyzing the physical properties of the mucus.
During the study, participants will receive azithromycin tablets by mouth, with a maximum daily dose of 500 mg. Throughout the year-long study, patients will have regular check-ups to monitor their breathing symptoms, measure their lung function, and assess their quality of life. The study will track how often patients experience worsening of their COPD symptoms, known as exacerbations, which can range from mild to severe enough to require hospitalization.
France 
